Back to Search
Start Over
Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
- Source :
-
Anais brasileiros de dermatologia [An Bras Dermatol] 2021 Jul-Aug; Vol. 96 (4), pp. 458-471. Date of Electronic Publication: 2021 May 28. - Publication Year :
- 2021
-
Abstract
- Cutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by infiltration of the skin by mature malignant T cells. Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, accounting for more than 60% of cases. Mycosis fungoides in the early-stage is generally an indolent disease, progressing slowly from some patches or plaques to more widespread skin involvement. However, 20% to 25% of patients progress to advanced stages, with the development of skin tumors, extracutaneous spread and poor prognosis. Treatment modalities can be divided into two groups: skin-directed therapies and systemic therapies. Therapies targeting the skin include topical agents, phototherapy and radiotherapy. Systemic therapies include biological response modifiers, immunotherapies and chemotherapeutic agents. For early-stage mycosis fungoides, skin-directed therapies are preferred, to control the disease, improve symptoms and quality of life. When refractory or in advanced-stage disease, systemic treatment is necessary. In this article, the authors present a compilation of current treatment options for mycosis fungoides and Sézary syndrome.<br /> (Copyright © 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1806-4841
- Volume :
- 96
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Anais brasileiros de dermatologia
- Publication Type :
- Academic Journal
- Accession number :
- 34053802
- Full Text :
- https://doi.org/10.1016/j.abd.2020.12.007